Related Experiment Video
Updated: Sep 19, 2025
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Self-enhanced ROS-responsive camptothecin prodrug nanoparticles elicit safe and efficient intravesical instillation
Kunpeng Liu1, Binbin Jiao2, Guan Zhang3
1The State Key Laboratory of Organic-inorganic Composites, Beijing Laboratory of Biomedical Materials, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Abstract:
Bladder cancer remains a significant clinical challenge, necessitating the development of innovative therapeutic strategies. Recent advancements have highlighted the potential of reactive oxygen species (ROS)-responsive drug delivery systems in cancer therapy. In this study, we introduce a novel treatment approach utilizing a ROS-responsive camptothecin (CPT) prodrug encapsulated within a chitosan nanocarrier, named CACPT. Cinnamaldehyde (CA), acting as a ROS generator, forms thioketal bonds with CPT to create a prodrug that responds selectively to the elevated ROS levels within the tumor microenvironment. Upon exposure to high ROS conditions, these thioketal bonds are cleaved, resulting in the simultaneous release of CPT and CA. The liberated CA further enhances ROS production, establishing a positive feedback loop that amplifies the therapeutic effect. The use of amphiphilic chitosan nanocarriers enhances the retention and penetration of the prodrug within bladder tissue, optimizing its therapeutic potential. Our experimental findings demonstrate that this self-enhanced ROS-responsive release promotes increased cellular uptake and significantly enhances the anticancer efficacy of CACPT. These results position CACPT as a promising candidate for intravesical therapy in bladder cancer, potentially overcoming current limitations in treatment options. The innovative combination of ROS-responsive mechanisms and chitosan nanocarriers represents a paradigm shift in bladder cancer therapeutics, offering a multifaceted approach with substantial promise for clinical translation.
Insights
This study introduces CACPT, a novel bladder cancer treatment. This reactive oxygen species (ROS)-responsive camptothecin (CPT) prodrug in chitosan nanocarriers enhances anticancer efficacy through a self-amplifying ROS feedback loop.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Bladder cancer presents significant therapeutic challenges.
- Reactive oxygen species (ROS)-responsive drug delivery systems show promise for cancer therapy.
- Novel strategies are needed to improve bladder cancer treatment efficacy.
Purpose of the Study:
- To develop and evaluate a novel ROS-responsive camptothecin (CPT) prodrug encapsulated in chitosan nanocarriers (CACPT) for bladder cancer treatment.
- To investigate the self-enhanced ROS-responsive release mechanism of CACPT.
- To assess the therapeutic potential of CACPT for intravesical bladder cancer therapy.
Main Methods:
- Synthesis of a ROS-responsive CPT prodrug using cinnamaldehyde (CA) and thioketal bonds.
- Encapsulation of the prodrug within amphiphilic chitosan nanocarriers.
- Evaluation of ROS-responsive drug release, cellular uptake, and anticancer efficacy in vitro and in vivo.
Main Results:
- CACPT demonstrated selective drug release in response to elevated ROS levels in the tumor microenvironment.
- The released CA amplified ROS production, creating a positive feedback loop.
- Chitosan nanocarriers improved drug retention and penetration in bladder tissue.
- CACPT significantly enhanced cellular uptake and anticancer efficacy compared to free CPT.
Conclusions:
- CACPT represents a promising intravesical therapeutic agent for bladder cancer.
- The self-enhanced ROS-responsive release mechanism offers a novel strategy to overcome treatment limitations.
- This approach holds potential for clinical translation in bladder cancer therapy.
